^
    Back
    Association details:
    Biomarker:TET2 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Vyxeos (cytarabine/daunorubicin liposomal formulation) (DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

    Excerpt:
    ...- The presence of any leukemia associated mutation as detected by DNA sequencing, except mutations in DNMT3A, TET2, or ASXL1....
    Trial ID:
    NCT04526288
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    1911 Distinct Clinical and Genetic Factors Predict Early Versus Late Mortality in AML Patients Undergoing Induction Chemotherapy

    Published date:
    11/04/2020
    Excerpt:
    We identified 290 consecutive adult patients treated with standard induction chemotherapy (“7+3” with cytarabine and an anthracycline, or CPX-351) for newly diagnosed AML...mutations in TET2 or RUNX1 were independently associated with death within 60 days.
    Secondary therapy:
    cytarabine